Ignite Creation Date:
2025-12-25 @ 2:40 AM
Ignite Modification Date:
2026-01-08 @ 4:54 PM
Study NCT ID:
NCT04351334
Status:
COMPLETED
Last Update Posted:
2024-09-19
First Post:
2020-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns
Sponsor:
Pfizer
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
B7461031
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None